EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins

Sylvie Chabot, Tahir Malik, Lila Saye, Martina Kosikova, Hyeog Kang, Zhiping Ye, Matthew Memoli, Marian Major, Jan-Willem de Gier, Robert Daniels

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2025.110974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Sylvie Chabot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Electronic addr…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral, Spike Glycoprotein, Coronavirus. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, U.S. Food and Drug Administration, Vetenskapsrådet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant surface antigens from enveloped viruses are commonly produced without the transmembrane domains to avoid difficulties associated with membrane protein expression and purification. Here, we overcame these challenges by fusing several SARS-CoV-2 envelope proteins to green fluorescent protein and a Strep-tag to facilitate protein detection and purification. This approach simplified the insect cell expression optimization and purification of recombinant prefusion stabilized full-length spike (rS-GFP), membrane (rM-GFP) and envelope (rE-GFP) proteins from the ancestral SARS-CoV-2 strain. We then used the isolated membrane proteins to develop an Enzyme-linked immunosorbent assay that leverages the Strep-tag for proper antigen display and GFP fluorescence for coating consistency. Initial tests with SARS-CoV-2 patient samples from 2020 (n = 68) and healthy adult volunteer samples from 2022-24 (n = 19) revealed a range of rS-GFP reactivity but minimal rM-GFP and rE-GFP reactivity. Approximately 55% of the 2020 patient samples were S-positive compared to ∼85% of the more recent healthy volunteer samples, suggesting the more recent healthy individuals had increased exposure to SARS-CoV-2 antigens by infection or vaccination. Recombinant S (rS) without the green fluorescent protein yielded similar results and detected more S-positive samples than the recombinant receptor binding domain alone. Finally, we confirmed all the S-positive samples neutralized S-pseudotyped particles and found that the enzyme-linked immunosorbent assay data from rS and recombinant receptor binding domain can be combined to identify high and low neutralization titer samples. The results from this proof of concept study suggest a similar strategy could be applied to rapidly develop assays for other enveloped virus surface antigens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Antibodies, ViralSpike Glycoprotein, CoronavirusHumansEnzyme-Linked Immunosorbent AssayAnimalsRecombinant ProteinsGreen Fluorescent ProteinsCoronavirus M ProteinsCoronavirus Envelope Proteins

Stichwörter der Autor:innen

COVID-19coronavirusenvelope (E) proteinenveloped virus surface antigenshuman antibody responsesimmunoglobulin (IgG) measurementsmembrane (M) proteinmembrane protein purificationspike (S) antigen

Substanzen

Antibodies, ViralSpike Glycoprotein, CoronavirusRecombinant ProteinsGreen Fluorescent Proteinsspike protein, SARS-CoV-2envelope protein, SARS-CoV-2membrane protein, SARS-CoV-2Coronavirus M ProteinsCoronavirus Envelope Proteins

Autor:innen und Institutionen

  • Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address: schabot.phd@gmail.com.
  • Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Laboratory of Infectious Diseases Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda…
  • Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden.
  • Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address: robert.daniels@fda.hhs.gov.

Förderung

  • National Institute of Allergy and Infectious Diseases
  • U.S. Food and Drug Administration
  • Vetenskapsrådet
  • Carl Tryggers Stiftelse för Vetenskaplig Forskning
  • Division of Intramural Research

Zitieren

APA

Chabot, S., Malik, T., Saye, L., Kosikova, M., Kang, H., Ye, Z., Memoli, M., Major, M., de Gier, J. W., & Daniels, R. (2026). Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110974

Vancouver

Chabot S, Malik T, Saye L, Kosikova M, Kang H, Ye Z, et al. Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2025.110974

BibTeX
@article{Chabot2026,
  author = {Chabot, Sylvie and Malik, Tahir and Saye, Lila and Kosikova, Martina and Kang, Hyeog and Ye, Zhiping and Memoli, Matthew and Major, Marian and de Gier, Jan-Willem and Daniels, Robert},
  title = {Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2025.110974}
}
Kostenlos starten →